Business · Markets · 2 hrs ago
Australian biotech shares fell in October despite commercial progress
The next 40 largest Australian biotechs lost almost 10% in October, while the broader Australian market gained about 1%.
The figures exclude the four biggest biotech companies, and 30 of the 40 saw their share prices fall.
The declines came despite commercial progress at some companies, with many falls linked to weak investor sentiment or slower-than-expected business growth.
Clever Culture Systems has announced a second device, APAS Revolution, aimed at smaller drug-making facilities.
The new product lifts its estimated potential market to US$4.3 billion, and the company has secured commitments for $2.6 million to develop it.
Customer evaluations are expected in 2027, with launch planned for 2028.
Separately, Orthocell’s partner Marine Biomedical has received US Food and Drug Administration clearance for its marine-derived bone graft, PearlBone; Avita Medical is due to announce quarterly figures on Friday.
The next 40 largest Australian biotechs, excluding the Big Four, lost almost 10% of their value in October, according to Biotech Daily.
The broader market gained about 1% during the month.
The falls came despite commercial progress by medical device and diagnostics companies.
Clever Culture Systems unveiled a second device that it says will expand its potential market by 50%.
The company expects to provide the new device for customer evaluation in 2027 and launch it in 2028.
- Who
- The next 40 largest Australian biotechs, excluding the Big Four.
- What
- They lost almost 10% of their value in October despite commercial progress by some companies.
- When
- October; the article was published on 3 November 2026.
- Where
- Australia’s biotech market, including companies listed on the ASX.
- Why
- The article cites investor indifference, general market malaise and, in some cases, slower-than-expected commercial progress.
This story does not have two clearly opposing sides.
The next 40 largest biotechs, excluding the Big Four, lost almost 10% of their value.
Stockhead reported the October share performance and Clever Culture Systems’ new product plans.
Clever Culture Systems expects to provide APAS Revolution for customer evaluation.
Clever Culture Systems expects to launch APAS Revolution.
- October performance
- Almost 10% decline for the next 40 largest biotechs, excluding the Big Four
- Broader market
- About 1% gain in October
- Clever Culture potential market
- US$4.3 billion, a 50% increase
- APAS Revolution funding
- $2.6 million in commitments
- APAS Revolution potential units
- 3,400
- Planned launch
- 2028